prolgolimab

Prolgolimab is a recombinant human immunoglobulin G1 (IgG1) monoclonal antibody that targets the programmed cell death protein 1 (PD-1) receptor on T cells. It acts as an immune checkpoint inhibitor by blocking the interaction between PD-1 and its ligands, thereby enhancing T-cell mediated antitumor responses. Prolgolimab features a modified Fc fragment with the “LALA” mutation (Leu234Ala/Leu235Ala), which minimizes effector functions such as binding to Fcγ receptors on macrophages, reducing antibody-dependent phagocytosis of activated T lymphocytes and potentially improving antitumor efficacy. Developed by Biocad in Russia, it is approved for first-line treatment of unresectable or metastatic melanoma and advanced non-small cell lung cancer. Clinical trials are ongoing for other indications including cervical cancer, colorectal cancer, and Hodgkin's disease[3][4][6].

Brand names

Forteca

Other names

Anti-PD-1 monoclonal antibodyAnti-PD1 monoclonal antibodyAnti-PD 1 monoclonal antibodyAnti PD-1 mAb